Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418276 | 0.84 | HRH1 (0.49) | HRH1ALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL4411032 | 0.81 | POLB (0.54) | MEN1KMT2AHRH1TP53TSHR | |
| SCHEMBL4412067 | 0.75 | MAPT (0.50) | MEN1KMT2AALDH1A1MAPTNPBWR1 | |
| SCHEMBL415765 | 0.74 | MAPK1 (0.47) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL7119605 | 0.74 | RPS6KA3 (0.45) | MEN1KMT2ATP53ALDH1A1KDM4E | |
| SCHEMBL4407294 | 0.74 | ALDH1A1 (0.58) | MEN1KMT2ATSHRALDH1A1KDM4E | |
| SCHEMBL416660 | 0.72 | GAA (0.53) | HRH1ALDH1A1KDM4EGAAPOLB | |
| SCHEMBL1077128 | 0.72 | NPC1 (0.51) | MEN1KMT2ATP53TSHRALDH1A1 | |
| Water SCHEMBL17103297 | 0.71 | NPC1 (0.50) | MEN1KMT2ATP53TSHRALDH1A1 | |
| SCHEMBL4083350 | 0.71 | TSHR (0.39) | MEN1KMT2AHRH1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1523475-B1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-12-23 | — | — | EP | disclosed |
| CN-1304371-C | Heterocyclically substituted benzoylureas, medicaments thereof and use for producing medicaments | AVENTIS PHARMA GMBH (DE) | 2007-03-14 | — | — | CN | disclosed |
| US-20070021474-A1 | Heterocyclically Substituted Benzoylureas, Process For Their Preparation and Their Use as Pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| US-7138414-B2 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-21 | — | — | US | disclosed |
| CN-1668593-A | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA GMBH (DE) | 2005-09-14 | — | — | CN | disclosed |
| EP-1523475-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-05 | — | — | US | disclosed |
| WO-2004007455-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLUREAS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021474-A1 | Heterocyclically Substituted Benzoylureas, Process For Their Preparation and Their Use as Pharmaceuticals | SLC5A2, CYP1A2, HBB | MEN1 1797/4885KMT2A 2633/4885HRH1 634/4885 |
| US-20040152743-A1 | Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals | SLC5A2, CYP1B1, CYP2C19 | MEN1 1171/4885KMT2A 3209/4885HRH1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.